| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | July 29, 2003 |
| PATENT TITLE |
Methods of treating viral infections using antiviral liponucleotides |
| PATENT ABSTRACT |
Compounds are disclosed for treating AIDS, herpes, and other viral infections by means of lipid derivatives of antiviral agents. The compounds consist of nucleoside analogues having antiviral activity which are linked, commonly through a phosphate group at the 5' position of the pentose residue, to one of a selected group of lipids. The lipophilic nature of these compounds provide advantages over the use of the nucleoside analogue alone. It also makes it possible to incorporate them into the lamellar structure of liposomes, either alone or combined with similar molecules. In the form of liposomes, these antiviral agents are preferentially taken up by macrophages and monocytes, cells which have been found to harbor the target HIV virus. Additional site specificity may be incorporated into the liposomes with the addition of ligands, such as monoclonal antibodies or other peptides or proteins which bind to viral proteins. Effective nucleoside analogues are dideoxynucleosides, azidothymine (AZT), and acyclovir; lipid groups may be glycolipids, sphingolipids, phospholipids or fatty acids. The compounds persist, after intracellular hydrolysis, as phosphorylated or non-phosphorylated antiviral nucleosides. The compounds are effective in improving the efficacy of antiviral nucleoside analogues by prolonging the antiviral activity after the administration of the drug has ended, and in preventing retroviral replication in HIV infections which have become resistant to therapy with conventional forms of the antiretroviral agents. |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | May 1, 2001 |
| PATENT REFERENCES CITED |
Nasr, Mohamed et al., "Computer-assisted structure-activity correlations of dideocynucleoside analogs as potential anti-HIV drugs (mini-review)", Antiviral Research, 14:125-148 (1990). Nasr, Mohamed et al., "Computer-assisted structure-activity correlations of halodideocynucleoside analogs as potential anti-HIV drugs", AIDS Research and Human Retroviruses, 8:135-144 (1992). Hostetler et al., International Conference on AIDS, p. 536, Th.co.o. 18 (abs.) (1989). Lehninger, Biochemistry 2nd ed., Worths Publishers, Johns Hopkins University, pp. 291-294 (1975). Hess, G. et al., Inhibition of Hepatitis B Virus Deoxyribonucleic Acid Polymerase . . . , Antimicrobial Agents and chemotherapy, 19(1):44-50 (1981). Kassanides, C. et al., Inhibition of Duck Hepatitis B Virus Replication . . . , Gastroenterology, 97:1275-1280 (1989). Lee, B. et al., in Vitro and In Vivo Comparison of the Abilities of Purine . . ., Antimicrobial Agents and Chemotherapy, 33:336-339 (1989). Matthes, E. et al., Potent Inhibition of Hepatitis B Virus Production in Vitro . . . , Antimicrobial Agents and Chemotherapy, 34:1986-1990 (1990). Sherpof, G.L. et al., In Vivo Uptake and Processing of Liposomes . . . , NATO ASI Series Ser. A: Targeting Drugs, 155:109-120 (1988). Spanjer, H. et al., Intrahepatic Distribution of Small Unilamellar Liposomes . . . , Biochem. Biophys. Acta, 863:224-230 (1986). Yoshikawa, M. et al., A Novel Method for Phosphorylation of Nucleosides to 5'-nucleotides, Tetrahedron Lett, 50:5065-5068 (1967). Yoshikawa, M. et al., Studies of Phosphorylation III, Selective Phosphorylation . . . , Bull. Chem. Soc. Japan, 42:3205-3208 (1967). Berdel et al., Antineoplastic Activity of Conjugates of Lipids and 1-B-D-arabinofuranosylcytosine, Lipids, 22(11):943-946 (1987). Hostetler et al., Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides, J. Biol. Chem., 265(11):6112-6117 (1990). Ryu, Ross, Matsushita, MacCoss, Hong and West, Phospholipid-Nucleoside Conjugates. 3. Syntheses and Preliminary Biological Evaluation of 1-.beta.-D-Arabinofuranosylcytosine 5'-Monophosphate-L-1,2-Dipalmitin and Selected Darabinofuranosylcytosine 5'-Diphosphate-L-1,2-Diacylglycerols, J. Med. Chem. 25:1322-1329 (1982). Bennett, Jr., Shannon, Allan and Arnett, Studies on the Biochemical Basis For the Antiviral Activities of some Nucleoside Analogs, Annals New York Academy of Sciences, 255:342-358 (1975). Montgomery, The Design of Chemotherapeutic Agents, Accounts of Chemical Research 19:293-300 (1986). DeClercq, Balzarini, Descamps and Eckstein, Antiviral, Antimetabolic and Antineoplastic Activities of 2'-or 3'-amino or -asido-substituted deoxyribonucleosides, Biochemical Pharmacology, 29:1849-1851 (1980). Price, Banerjee and Acs, Inhibition of the Replication of Hepatitis B Virus by the Carbocyclic Analogue of 2'-deoxyguanosine, Proc. Natl. Acad. Sci. USA 86:8541-8544. (1989). Scherphof, Daemen, Spanjer and Roerdink, Liposomes in Chemo-and Immunotherapy of Cancer, Lipids 22(11):891-896 (1987). Yang, Turcotte and Steim, Biophysical Properties of Cytidine Diphosphate Diacylglycerol in Solution, Biochimica et Biophysica Acta 834:364-375 (1985). Hantz, Allaudeen, Ooka, DeClercq and Trepo, Inhibition of Human dn Woodchuck Hepatitis Virus DNA Polymerase by the Triphosphates of Acyclovir, 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine, Antiviral Research 4:187-199 (1984). Matsushita, Ryu, Hong and MacCoss, Phospholipid Derivatives of Nucleoside Analogs as Prodrugs with Enhanced Catabolic Stability, Cancer Research 41:2707-2713 (1981). Agranoff et al. Cytidine Diphosphate-DL-Dipalmitin, Biochemical Preparations 10:47-51 (1963). Alving, Steck, Chapman, Jr., Waits, Hendricks, Swartz, Jr. and Hanson, Therapy of Leishmaniasis: Superior Efficacious of Liposome-Encapsulated Drugs, Proc. Natl. Acad. Sci. USA 75:2959-2963 (1978). Bangham et al. (1965) Diffusion of Univalent Ions Across the Lamellac of Swollen Phospholipids, J. Mol. Biol. 13:238-252. Benjamins and Agranoff, Distribution and Properties of CDP-Diglyceride:Inositol Transferase From Brain, J. Neurochemistry 16:513-527 (1969). Black and Watson, The Use of Pentostam Liposomes in the Chemotherapy of Experimental Leishmaniasis, Transactions of the Royal Society of Tropical Medicine and Hygiene 71:550-552 (1977). Bligh and Dyer, A Rapid Method of Total Lipid Extraction and Purification, Canadian Journal of Biochemistry and Physiology 37:911-917 (1959). Brown, D.A. et al., An X-ray examination of long-chain alkyl dihydrogen phosphates and dialkyl hydrogen phosphates and their sodium salts, J. Chem. Soc. (London), pp. 1584-1588 (1955). Cao, O, Choy and Chan, Regulation by Vitamin E of Phosphatidylcholine Metabolism in Rat Heart, Biochem. J. 247:135-140 (1987). Carman and Fischl, Modification of the Agranoff-Suomi method of the synthesis of CDP-Diacylglycerol, J. of Food Biochemistry 42:53-59 (1980). Fischl, Richman, Grieco, Gottilieb, Volberding, Laskin, Leedom, Groopman, Mildvan, Schooley, Jackson, Durack, Phil, King, The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with Aids and Aids-Related Complex, The New England Journal of Medicine 317:185-191 (1987). Fukunaga, Miller, Hostetler and Deftos, Liposome Entrapment Enhances the Hypocalcemic Action of Parenterally Administered Calcitonin, Endocrinology 115:757-761 (1984). Heath, Lopez, Piper, Montgomery, Stern and Papahadjopoulos, Liposome-mediated Delivery of Pteridine Antifolates to Cells in Vitro: Potency of Methotrexate, and its a and ? Substituents, Biochimica et Biophysica Acta 862:72-80 (1986). Herman, Rahman, Ferrans, Vick and Schein, Prevention of Chronic Doxorubicin Cardiotoxicity in Beagles By Liposomal Encapsulation, Cancer Research 43:5427-5432 (1983). Ho and Neil, Pharmacology of 5'-Esters of 1-.beta.-D-Arabinofuranosylcytosine, Cancer Research 37:1640-1643 (1977). Huang, A., Huang, L. and Kennel, Monoclonal Antibody Covalently Coupled with Fatty Acid, J. Biological Chemistry 255:8015-8018 (1980). Kende, Alving, Rill, Swartz, Jr. and Canonico, Enhanced Efficacy of Liposome-Encapsulated Ribavirin Against Rift Valley Fever Virus Infection in Mice, Antimicrobial Agents and Chemotherapy 27:903-907 (1985). Koenig, Gendelman, Orenstein, Dal Canto, Pezeshkpour, Yungbluth, Janotta, Aiksamit, Martin and Fauci, Detection of AIDS Virus in Macrophages in Brain Tissue from AIDS Patients with Encephalopathy, Science 233:1089-1093 (1986). Kim et al. (1983) Preparation of Multivesicular Liposomes, Biochimica et Biophysica Acta, 728:339-348. Leserman, Barbet and Kourilsky, Targeting to Cells of Fluorescent Liposomes Covalently Coupled with Monoclonal Antibody or Protein A, Nature 288:602-604 (1980). Lopez-Berestein, Liposomal Amphotericin B in the Treatment of Fungal Infections, Ann. Int. Med. 105:130-131 (1986). MacCoss, Ryu and Matsushita, The Synthesis, Characterization, and Preliminary Biological Evaluation of 1-.beta.-D-Arabinofuranosylcytosine-5'-Diphosphate-L-1,2-Dipalmitin, Biochemical and Biophysical Research Communications 85:714-723 (1978). Martin, Tippie, McGee and Verheyden, Synthesis and Antiviral Activity of Various Esters of 9-[(1,3-Dihydroxy-2-Propoxy)methyl]guanine, J. Pharmaceutical Sciences 76:180-184 (1987). Welch, Larsson, Ericson, Oberg, Datema and Chattopadhyaya, The Chemical Synthesis and Antiviral Properties of an Acyclovir-Phospholipid Conjugate, Acta Chemica Scandinavica B 39:47-54 (1985). Mayer, Hope and Cullis, Vesicles of Variable Sizes Produced by a Rapid Extrusion Procedure, Biochimica et Biophysica Acta 858:161-168 (1896). Mayhew, Lazo, Vail, King and Green, Characterization of Liposomes Prepared Using a Microemulsifier, Biochimica et Biophysica Acta, 775:169-174 (1984). Murthy and Agranoff, Stereospecific Synthesis and Enzyme Studies of CDP-Diacylglycerols, Biochimica et Biophysica Acta 712:473-483 (1982). Norley, Huang and Rouse, Targeting of Drug Loaded Immunoliposomes to Herpes Simplex Virus Infected Corneal Cells: An Effective Means of Inhibiting Virus Replication in Vitro, J. Immunology 136:681-685 (1986). Olson et al. (1979) Preparation of Liposomes of Defined Size Distribution by Extrusion Through Polycarbonate Membranes, Biochimica et Biophysica Acta 557:9-23. Osto, Liposomes, Sci. Am. 256-103-111 (1987). Poorthuis and Hostetler, Studies on Nucleotide Diphosphate Diacylglycerol Specificity of Acidic Phospholipid Biosynthesis in Rat Liver Subcellular Fractions, Biochimica et Biophysica Acta 431:408-415 (1976). Poste, Kirsh, and Koestler, The Challenge of Liposome Targeting in Vivo, in Liposome Technology, vol. III. G. Gregoriadis, Ed., CRC Press, Boca Raton, pp. 1-28. Prottey and Hawthorne, The Biosynthesis of Phosphatidic Acid and Phosphatidylinositol in Mammalian Pancreas, Biochem. J. 105:379-391 (1967). Raetz and Kennedy, Function of Cytidine Diphosphate-Diglyceride and Deoxycytidine Diphosphate-Diglyceride in the Bio-Genesis of Membrane Lipids in Escherichia coli, J. Biological Chemistry 248:1098-1105 (1973). Richman, Fischl, Grieco, Gottlieb, Volberding, Laskin, Leedom, Groopman, Mildvan, Hirsch, Jackson, Durack, Phil and Nusinoff-Lehrman, The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex, The New England Journal of Medicine 317:192-197 (1987). Richman, Kornbluth and Carson, Failure of Dideoxynucleosides to Inhibit Human Immunodeficiency Virus Replication in Cultured Human Macrophages, J. Experimental Medicine 166:1144-1149 (1987). Rittenhouse, Seguin, Fisher and Agranoff, Properties of a CDP-Diglyceride Hydrolase from Guinea Pig Brain, J. Neurochemistry 36:991-999 (1981). Rosenthal and Geyer, A Synthetic Inhibitor or Venom Lecithinase A, J. Biological Chemistry 235:2202-2206 (1960). Salahuddin, Rose, Groopman, Markham and Gallo, Human T Lymphotropic Virus Type III Infection of Human Alveolar Macrophages, Blood 68:281 (1986). Scherphof, Liposomes in Biology and Medicine (a biased review) in Lipids and Biomembranes, Past. Present and Future, op den Kamp, J., Roelofsen, B. and Wirtz, K.W.Al, Eds., Elsevier North Holland, Amsterdam, pp. 113-136, (1986). Shuto, Ueda, Itoh, Endo, Kukukawa, Imamura, Tsujino, Matsuda and Ueda, Synthesis of 5'-Phosphatidylnucleosides by Phospholipase Dcatalyzed Transphosphatidylation, Nucleic Acids Research Symposium Series No. 17, pp. 73-76 (1986). Szoka and Papahadjopoulos (1978) Procedure for Preparation of Liposomes With Large Internal Aqueous Space and High Capture by Reverse-Phase Evaporation, Proc. Natl. Acad. Sci. USA 75:4194-1498. Ter Schegget, Bosch, Van Baak, Hostetler and Borst, The Synthesis and Utilization of dCDP-Diglyceride By A Mitochondrial fraction From Rat Liver, Biochimica et Biophysica Acta 239:234-242 (1971). Toorchen and Topai, Mechanisms of Chemical Mutagenesis and Carcinogenesis: Effects on DNA Replication of Methylation at the O6-Guanine Position of dGTP, Carcinogenesis 4:1591-1597 (1983). Turcotte, Srivastava, Meresak, Rizkalla, Louzon and Wunz, I. Chemical Synthesis of CDP-Diacylglycerol Analogs Containing the Cytosine Arabinoside Moiety, Biochimica et Biophysica Acta 619:604-618 (1980). Turcotte, Srivastava, Steim, Calabresi, Tibbetts and Chu, Cytotoxic Liponucleotide Analogs, Biochimica et Biophysica Acta 619:619-631 (1980). |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What is claimed is: 1. A method for inhibiting a viral polymerase in a virally infected mammalian cell without killing the cell, said method comprising administering to a mammal in need thereof an effective antiviral amount of a liponucleotide compound comprising: an antiviral nucleoside analogue having an ability to selectively inhibit said viral polymerase enzyme without killing the cell; and a lipid moiety selected from the group consisting of glycerolipids having the structure ##STR19## wherein said R.sub.1 and R.sub.2 independently have from 0 to 6 sites of unsaturation, and have the structure CH.sub.3 --(CH.sub.2).sub.a --(CH.dbd.CH--CH.sub.2).sub.b --(CH.sub.2).sub.c --Y wherein the sum of a and c is from 1 to 23; and b is 0 to 6; and wherein Y is selected from the group consisting of --CH.sub.2 --O, --CH.dbd.CH--O--, --CH.sub.2 --S--, and --CH.dbd.CH--S--; wherein the antiviral nucleoside analogue is covalently bound to the lipid moiety through a mono-phosphate linkage to the 5' carbon of the pentose residue of the nucleoside analogue corresponding to the 5' carbon of naturally occurring nucleosides. 2. The method of claim 1, wherein said nucleoside analogue is selected from the group consisting of 2',3'-dideoxycytidine; 2',3'-dideoxyguanosine; 2',3'-dideoxyadenosine; 2',3'-dideoxyinosine; 2,6-diaminopurine 2',3'-dideoxyriboside; 2',3'-didehydrothymidine; 2',3'-didehydrocytidine carbocyclic; 2',3'-didehydroguanosine; 3'-azido-3'-deoxythymidine; 3'-azido-3'-deoxyguanosine; 2,6-diaminopurine-3'-azido-2',3'-dideoxyriboside; 3'-fluoro-3'-deoxythymidine; 3'-fluoro-2',3'-dideoxyguanosine; 2',3'-dideoxy-2'-fluoro-ara-adenosine; 2,6-diaminopurine-3'-fluoro-2',3'-dideoxyriboside; 9-(4-hydroxy-1',2'-butadienyl) adenine; 3-(4-hydroxy-1',2'-butadienyl) cytosine; 9-(2-phosphonylmethoxyethyl) adenine; 3-phosphonomethoxyethyl-2,6-diaminopurine; ganciclovir; 3'-azido-2',3'-dideoxy-5-chlorouridine (AzddClU); 3'-azido-2',3'-dideoxy-5-methylcytosine (AzddMeC); 3'-azido-2',3'-dideoxy-5-methylcytosine-N4OH (AzddMeC N4OH); 3'-azido-2',3'-dideoxy-5-methylcytosine-N4Me (AzddMeC N4Me); 3'-azido-2',3'-dideoxy-5-ethyluridine (AzddEtU); 3'-azido-2',3'-dideoxyuridine (AzddU); 3'-azido-2',3'-dideoxycytosine (AzddC); 3'-azido-2',3'-dideoxy-5-fluorocytosine (AzddFC); 3'-azido-2',3'-dideoxy-5-bromouridine (AzddBrU); 3'-azido-2',3'-dideoxy-5-fluorouridine (AzddTU); 3'-fluoro-2',3'-dideoxy-5-chlorouridine (FddClU); 3'-fluoro-2',3'-dideoxyuridine (3'FddU); 3'-fluoro-2',3'-dideoxythymidine (3'FddT); 3'-fluoro-2',3'-dideoxy-5-bromouridine (3'FddBrU); 3'-fluoro-2',3'-dideoxy-5-ethyluridine (3'FddEtU); 2',3'-dideoxy-2',3'-didehydrothymidine (D4T); 2',3'-dideoxy-2',3'-didehydrocytidine (D4C); 2',3'-dideoxy-2',3'-didehydro-5-methylcytidine (D4MeC); 2',3'-dideoxy-2',3'-didehydroadenosine (D4A); 5-fluoro-2',3'-dideoxycytidine (5FddC); 2,6-diaminopurine-2',3'-dideoxyriboside (ddDAPR); 5-methyl-2',3'-dideoxyadenosine (ddMeA); 3'-azido-2',3'-dideoxy-diaminopurine (N.sub.3 ddDAPR); 3'-azido-2',3'-dideoxyguanosine (3N.sub.3 ddG); 3'-fluoro-2',3'-dideoxy-diaminopurine (3FddDAPR); 3'-fluoro-2',3'-dideoxyguanosine (3FddG); 3'-fluoro-2',3'-dideoxy-arabinofuranosyl-adenine (3Fddara-A); 3'-fluoro-2',3'-dideoxyadenosine (3FddA); and 2',3'-dideoxy-3'thiacytidine (3TC). 3. The method of claim 1 wherein said lipid moiety is selected from the group consisting of 1,2-O-alkylglycerols and 1,2-S-alkylglycerols. 4. The method of claim 1 wherein said lipid moiety is selected from the group consisting of 1-S-alkyl,2-O-alkylglycerols and 1-O-alkyl,2-S-alkylglycerols. 5. The method of claim 1 wherein said inhibition of said viral polymerase by said liponucleotide is greater than an inhibition of said viral polymerase by a corresponding free nucleoside. 6. The method of claim 1 wherein said liponucleotide comprises 1-S-dodecyl, 2-O-decylglycero-phospho-3'-azido-3'deoxythymidine. 7. The method of claim 1 wherein the antiviral nucleotide is 1-S-dodecyl,2-O-decylglycero-phospho-2',3'-dideoxycytosine. 8. The method of claim 1 wherein the antiviral nucleotide is 1-S-dodecyl,2-O-decylglycero-phospho-2',3'-didehydro, 2',3'-dideoxythymidine. 9. The method of claim 1 wherein the antiviral nucleotide is 1-S-dodecyl,2-O-decylglycero-phospho-2',3'-dideoxyinosine. 10. The method of claim 1 wherein the antiviral nucleotide is 1-S-dodecyl,2-O-decylglycero-phospho-9-[(1,3-dihydroxy-2-propoxy)methyl]gu anine. 11. The method of claim 1 wherein the antiviral nucleotide is 1-S-dodecyl,2-O-decylglycero-phospho-2',3'-dideoxy-3'-thiacytidine. -------------------------------------------------------------------------------- |
| PATENT DESCRIPTION |
BACKGROUND OF THE INVENTION The present invention relates generally to the treatment of viral infections using lipid derivatives of antiviral nucleoside analogues. More particularly, the present invention relates to lipid, and especially phospholipid, derivatives of modified antiviral nucleoside analogues which can be integrated into the structure of liposomes, thereby forming a more stable liposomal complex which can deliver greater amounts of drugs to target cells with less toxicity. The publications and other reference materials referred to herein are hereby incorporated by reference, and are listed for convenience in the bibliography appended at the end of this specification. There has been a great deal of interest in recent years in the use of nucleoside analogues to treat viral infections. A nucleoside consists of a pyrimidine or purine base which is linked to ribose, a five-carbon sugar having a cyclic structure. The antiviral nucleoside analogues closely resemble natural nucleosides and are designed to inhibit viral functions by preventing the synthesis of new DNA or RNA. Nucleosides are enzymatically assembled into DNA or RNA. During DNA synthesis, free nucleoside triphosphates (nucleosides with three phosphate groups attached) react with the end of a growing DNA chain. The reaction involves the linking of the phosphate group at the 5' position on the incoming nucleoside triphosphate with the hydroxyl group at the 3' position of the sugar ring on the end of the forming DNA chain. The other two phosphate groups are freed during the reaction, thereby resulting in the addition of a nucleotide to the DNA chain. Nucleoside analogues are compounds which mimic the naturally occurring nucleosides sufficiently so that they are able to participate in viral DNA synthesis. However, the antiviral nucleoside analogues have strategically located differences in chemical structure which inhibit viral enzymes such as reverse transcriptase or which prevent further DNA synthesis once the analogue has been attached to the growing DNA chain. Dideoxynucleosides are antiviral compounds that lack the hydroxyl groups normally present at the second and third position of ribose. When a dideoxynucleoside is incorporated into a growing DNA chain, the absence of the 3-OH group on its ribose group makes it impossible to attach another nucleotide and the chain is terminated. Dideoxynucleosides are particularly useful in treating retroviral infections where viral replication requires the transcription of viral RNA into DNA by viral reverse transcriptase. Other nucleoside analogues include deoxynucleosides and nucleosides analogues having only a fragment of ribose or other pentose connected to the base molecule. Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV). HIV infects cells bearing the CD4 (T4) surface antigen, such as CD4+ helper lymphocytes, CD4+ monocytes and macrophages and certain other CD4+ cell types. The HIV infection of CD4+ lymphocytes results in cytolysis and cell death which contributes to the immunodeficiency of AIDS; however, CD4+ monocytes and macrophages may not be greatly harmed by the virus. Viral replication in these cells appears to be more prolonged and less cytotoxic than in lymphocytes, and as a result, monocytes and macrophages represent important reservoirs of HIV infection. It has recently been discovered that macrophages may serve as reservoirs of HIV infection even in certain AIDS patients who test negative for the presence of HIV antibodies. No effective cure is available for AIDS, although dideoxynucleosides have been shown to prolong life and to reduce the incidence of certain fatal infections associated with AIDS. Certain monocyte-derived macrophages, when infected with some strains of HIV, have been found to be resistant to treatment with dideoxycytidine, azidothymidine, and other dideoxynucleosides in vitro as shown by Richman, et al. (1). The resistance may be due in part to the low levels of dideoxynucleoside kinase which result in a reduced ability to phosphorylate AZT, ddC or ddA. Clearly, it would be useful to have more effective ways of delivering large amounts of effective antiviral compounds to macrophages infected with HIV or other viruses and other cells having viral infections. It would also be useful to have more effective ways of delivering antiviral compounds which not only increase their potency but prolong their efficacy. Dideoxynucleoside analogues such as AZT are the most potent agents currently known for treating AIDS, but in a recent human trial, serious toxicity was noted, evidenced by anemia (24%) and granulocytopenia (16%) (2,3). It is desirable, therefore, to provide a means for administering AZT and other dideoxynucleosides in a manner such that the toxic side effects of these drugs are reduced. Further, it is desirable to provide selective targeting of the dideoxynucleoside to monocyte/macrophages to enhance the efficiency of the drug against viral infection in this group of cells. One way to do this is to take advantage of the uptake of liposomes by macrophages. In 1965, Alex Bangham and coworkers discovered that dried films of phosphatidylcholine spontaneously formed closed bimolecular leaflet vesicles upon hydration (4). Eventually, these structures came to be known as liposomes. A number of uses for liposomes have been proposed in medicine. Some of these uses are as carriers to deliver therapeutic agents to target organs. The agents are encapsulated during the process of liposome formation and released in vivo when liposomes fuse with the lipids of cell surface membrane. Liposomes provide a means of delivering higher concentrations of therapeutic agents to target organs. Further, since liposomal delivery focuses therapy at the site of liposome uptake, it reduces toxic side effects. For example, liposomal antimonial drugs are several hundred-fold more effective than the free drug in treating leishmaniasis as shown independently by Black and Watson (5) and Alving, et al. (6). Liposome-entrapped amphotericin B appears to be more effective than the free drug in treating immunosuppressed patients with systemic fungal disease (7). Other uses for liposome encapsulation include restriction of doxorubicin toxicity (8) and diminution of aminoglycoside toxicity (9). As previously mentioned, it is now thought that macrophages are an important reservoir of HIV infection (10, 11). Macrophages are also a primary site of liposome uptake (12, 13). Accordingly, it would be desirable to utilize liposomes to enhance the effectiveness of antiviral nucleoside analogues in treating AIDS and other viral infections. The use of liposomes to deliver phosphorylated dideoxynucleoside to AIDS infected cells which have become resistant to therapy has been proposed in order to bypass the low dideoxynucleoside kinase levels. Attempts have also been made to incorporate nucleoside analogues, such as iododeoxyuridine (IUDR), acylovir (ACV) and ribavirin into liposomes for treating diseases other than AIDS. However, these attempts have not been entirely satisfactory because these relatively small water soluble nucleoside analogues tend to leak out of the liposome rapidly (14, 15), resulting in decreased targeting effectiveness. Other disadvantages include the tendency to leak out of liposomes in the presence of serum, difficulties in liposome formulation and stability, low degree of liposomal loading, and hydrolysis of liposomal dideoxynucleoside phosphates when exposed to acid hydrolases after cellular uptake of the liposomes. Attempts have also been made to combine nucleoside analogues, such as arabinofuranosylcytosine (ara-C) and arabinofuranosyladenine (ara-A), with phospholipids in order to enhance their catabolic stability as chemotherapeutic agents in the treatment of various types of cancer (16). The resulting agents showed a decreased toxicity and increased stability over the unincorporated nucleoside analogues. However, the resulting agents exhibited poor cellular uptake (16) and poor drug absorption (17). In order to use nucleoside analogues incorporated into liposomes for treating viral infections more effectively, it is desirable to increase the stability of the association between the liposome and the nucleoside analogue. In order to further enhance the effectiveness of these antiviral liposomes, it would be desirable to target the liposomes to infected cells or sites of infection. Greater specificity in liposomal delivery may be obtained by incorporating monoclonal antibodies or other ligands into the liposomes. Such ligands will target the liposomes to sites of liposome uptake capable of binding the ligands. Two different approaches for incorporating antibodies into liposomes to create immunoliposomes have been described: that of Huang and coworkers (18) involving the synthesis of palmitoyl antibody, and that of Leserman, et al. (19) involving the linkage of thiolated antibody to liposome-incorporated phosphatidylethanolamine (PE). The methods disclosed here apply not only to dideoxynucleosides used in the treatment of AIDS and other retroviral diseases, but also to the use of antiviral nucleosides in the treatment of diseases caused by other viruses, such as herpes simplex virus (HSV), human herpes virus 6, cytomegalovirus (CMV), hepatitis B virus, Epstein-Barr virus (EBV), and varicella zoster virus (VZV). Thus, the term "nucleoside analogues" is used herein to refer to compounds that can inhibit viral replication at various steps, including inhibition of viral reverse transcriptase or which can be incorporated into viral DNA or RNA, where they exhibit a chain-terminating function. SUMMARY OF THE INVENTION The invention provides a composition for use in treating viral infections, including HIV (AIDS), herpes simplex virus (HSV), human herpes virus 6, cytomegalovirus (CMV), hepatitis B virus, Epstein-Barr virus (EBV), and varicella zoster virus (VZV). The composition may contain, in addition to a pharmaceutically acceptable carrier, a lipophilic antiviral agent prepared by chemically linking an antiviral nucleoside analogue to at least one lipid species. The antiviral nucleoside analogue may be linked to the lipid through a monophosphate, diphosphate or triphosphate group. The invention, further, provides a method for incorporating such lipid derivatives of antiviral agents into liposomes for improved delivery of the antiviral agent. A liposome comprises a relatively spherical bilayer which is comprised wholly or in part of the above-described lipid derivatives of antiviral agents. The liposome may also contain pharmacologically inactive lipids. Further, the liposome may contain a ligand, such as a monoclonal antibody to a viral binding site (such as CD.sub.4), or other binding protein. Such a ligand provides additional specificity in the delivery site of the antiviral agent. The invention provides a method for incorporating such ligands into antiviral liposomes. In one preferred embodiment, the compound is a phosphatidyldideoxynucleoside or a dideoxynucleoside diphosphate diglyceride. In another, the lipid species may comprise at least one acyl ester, ether, or vinyl ether group of glycerol-phosphate. Phosphatidic acids having at least one acyl ester, ether, or vinyl ether group may also serve as a favored lipid species. In another embodiment, the nucleoside analogue is a purine or pyrimidine linked through a .beta.-N-glycosyl bond to a pentose residue that lacks at least one of the 2' or 3' carbons, but retains the 5' carbon, and the phosphate group is bound to the 5' carbon (i.e., what would have been the 5' carbon in a complete pentose moiety). In another embodiment of the invention, the lipid species is an N-acyl sphingosine. In some preferred embodiments, the acyl or alkyl groups of the lipid species, of whatever linkage, as for example ester, ether or vinyl ether, comprise 2 to 24 carbon atoms. In one variation, at least one of the acyl or alkyl groups is saturated. In another, at least one of the acyl or alkyl groups has up to six double bonds. In yet another embodiment, an acyl or alkyl group may be attached directly by ester or alkyl linkage to the 5'-hydroxyl of the nucleoside. In still another, the lipid moiety is a glyceride and the glyceride has two acyl groups that are the same or different. In still another embodiment of the invention, the lipid species is a fatty alcohol residue which is joined to a phosphate linking group through an ester bond. The compound may advantageously have from one to three phosphate groups, and at least one fatty alcohol ester, and may have two or more fatty alcohol residues that are the same or different in structure. These fatty alcohols are preferably linked to the terminal phosphate group of the compound. Moreover, the invention includes a composition wherein, in addition to the compound, the liposome further comprises phospholipids selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidylinositol and sphingomyelin. In one embodiment of the invention, the percentage of antiviral agent is 0.01 to 100 percent by weight of the liposome. In another embodiment, the liposome further comprises a ligand bound to a lipid substrate. The ligand may be an antibody, such as a monoclonal antibody to a viral antigen. The viral antigen could be gp41 or gp110 of HIV, or could be any other suitable viral antigen. In one embodiment, the ligand is CD4 receptor protein, or CD4 protein itself. Alternatively, the ligand is an antibody to CD4 or a protein or other substance that binds CD4. The invention also contemplates a composition for use in treating viral and retroviral infections, comprising a liposome formed at least in part of an lipophilic antiviral agent, the agent comprising a nucleoside analogue having a base and a pentose residue with at least one lipid species attached to the nucleoside analogue through a monophosphate, diphosphate or triphosphate linking group at the 5' hydroxyl of the pentose residue of the nucleoside analogue, and a pharmaceutically acceptable carrier therefore. Thus, there is provided a composition having antiviral properties, comprising an antiviral nucleoside analogue having a base portion comprising a substituted or unsubstituted purine or pyrimidine, and a sugar portion comprising a pentose residue, and a lipid moiety linked to the pentose residue, with the proviso that the composition is in the form of a liposome when the pentose residue is ribose and the base portion is cytosine, and when the pentose residue is arabinofuranose and the base portion is cytosine or adenine. In one embodiment, the nucleoside analogue is a nitrogenous base which is a purine, pyrimidine, or a derivative thereof, and the pentose residue is a 2',3'-dideoxy, 2',3'-didehydro, azido or halo derivative of ribose, or an acyclic hydroxylated fragment of ribose. The pentose residue may thus be a 2',3'-dideoxyribose, and the nucleoside analogue may be 2',3'-dideoxycytidine, 2',3'-dideoxythymidine, 2',3'-dideoxyguanosine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2,6 diaminopurine, 2',3'-dideoxyriboside. In another embodiment, the pentose residue is a 2',3'-didehydroribose and the nucleoside is 2',3'-didehydrothymidine, 2',3'-didehydrocytidine carbocyclic, or 2',3'-didehydroguanosine. In still another embodiment, the pentose residue is an azide derivative of ribose, and the nucleoside is 3'-azido-3'-deoxythymidine, 3'-azido-3'-deoxyguanosine, or 2,6-diaminopurine-3-azido-2',3'dideoxyriboside. In still another embodiment of the invention, the pentose residue is a halo derivative of ribose and the nucleoside is 3'-fluoro-3'-deoxythymidine, 3'-fluoro-2',3'-dideoxyguanosine, 2',3'-dideoxy-2'-fluoro-ara-adenosine, or 2,6-diaminopurine-3'-fluoro-2',3'-dideoxyriboside. The invention also includes halo derivatives of the purine or pyrimidine rings, such as, for example, 2-chloro-deoxyadenosine. Alternatively, the pentose residue is an acyclic hydroxylated fragment of ribose, and the nucleoside is 9-(4,-hydroxy-1',2'-butadienyl) adenine, 3-(4,-hydroxy-1',2'-butadienyl) cytosine, 9-(2-phosphonylmethoxyethyl)adenine or phosphonomethoxydiaminopurine. In accordance with another aspect of the invention, the nucleoside analogue is acyclovir, gancyclovir, 1-(2'-deoxy-2'-fluoro-1-.beta.-D-arabinofuranosyl)-5-iodocytosine (FIAC) or 1(2'-deoxy-2'-fluoro-1-.beta.-D-arabinofuranosyl)-5-iodouracil (FIAU). In all of the foregoing compositions, a monophosphate, diphosphate, or triphosphate linking group may be provided between the 5' position of the pentose residue and the lipid species. Alternatively, there may be an aliphatic bridge comprising two functional groups and having from 0 to 10 carbon atoms between the functional groups, the bridge joining the lipid and the pentose residue. In still further embodiments of the invention, the lipid species is a fatty acid, a monoacylglycerol, a diacylglycerol, or a phospholipid. The phospholipid may have a head group comprising a sugar or a polyhydric alcohol. Specific examples of phospholipids include bis(diacylglycero)-phosphate and diphosphatidylglycerol. Other examples of lipid species include D,L-2,3-diacyloxypropyl-(dimethyl)-beta-hydroxyethyl ammonium groups. In accordance with another aspect of the present invention, the lipid species comprises from 1 to 4 fatty acid moieties, each the moiety comprising from 2 to 24 carbon atoms. Advantageously, at least one fatty acid moiety of the lipid species is unsaturated, and has from 1 to 6 double bonds. Particular examples of these compositions include 3-phosphonomethoxyethyl-2,6-diaminopurine; 1,2-diacylglycerophospho-5'-(2',3'-dideoxy)thymidine. Specific compositions are provided having the formula: (L).sub.m --(W).sub.n --A--Q--Z wherein Z is the base portion of the nucleoside analogue, Q is the pentose residue, A is O, C, or S, W is phosphate, n=0 to 3, and L is a lipid moiety wherein m=1 to 5, and wherein each L is linked directly to a W except when n=0, in which case each L is linked directly to A. Also included are compositions having the formula: ##STR1## wherein Z is the substituted or unsubstituted purine or pyrimidine group of the nucleoside analogue, Q is the pentose residue, W is phosphate, A is O, C, or S, L.sub.1 is (CH.sub.2 --CHOH--CH.sub.2), and L is a lipid moiety. In one embodiment of the invention, with reference to the foregoing formulas, each L is independently selected from the group consisting of R, ##STR2## wherein R, R.sub.1 and R.sub.2 are independently C.sub.2 to C.sub.24 aliphatic groups and wherein R, R.sub.1 and R.sub.2 independently have from 0 to 6 sites of unsaturation, and have the structure CH.sub.3 --(CH.sub.2).sub.a --(CH.dbd.CH--CH.sub.2).sub.b --(CH.sub.2).sub.c --Y wherein the sum of a and c is from 1 to 23, and b is 0 to 6, and wherein Y is C(O)O--, C--O--, C.dbd.C--O--, C(O)S--, C--S--, or C.dbd.C--S--. In one embodiment of the foregoing compositions, the pentose residue comprises ribose, dideoxyribose, didehydroribose, or an azido or halosubstituted ribose, attached at the 9 position of the purine or at the 1 position of the pyrimidine. The present invention also provides a method for synthesizing a lipid derivative of an antiviral nucleoside, comprising the step of reacting an antiviral nucleoside, having a ribose hydroxyl group, with a phospholipid in the presence of a coupling reagent whereby the nucleoside is joined to the phospholipid by a phosphate bond at the position of the ribose hydroxyl group. In one preferred embodiment, the phospholipid is a diacyl phosphate. In another, the phospholipid is a phosphatidic acid or a ceramide. Also provided herein is a method of synthesizing a lipid derivative of an antiviral nucleoside, comprising the steps of reacting an antiviral nucleoside monophosphate with a reagent HL, wherein L represents a leaving group, to form a nucleoside PO.sub.4 -L, reacting the nucleoside PO.sub.4 -L with a phosphatidic acid to bind the acid to the nucleoside through a pyrophosphate bond. In one variation of the method, the nucleoside monophosphate is AZT 5'-monophosphate. Still a further method provided by the present invention is a method of synthesizing a glyceride derivative of a nucleoside analogue, comprising the step of joining a monoglyceride or diglyceride and an antiviral nucleoside monophosphate with a coupling agent in the presence of a basic catalyst. In one embodiment, the glyceride is 1-O-stearoylglycerol and the nucleoside is AZT monophosphate. Also a part of the present invention is a method for preparing a suspension of liposomes for use in treating viral and retroviral infections in a mammal, comprising providing a lipophilic antiviral agent comprising at least one lipid species attached to a nucleoside analogue through a monophosphate, diphosphate or triphosphate linking group at the 5' position of the pentose residue of the nucleoside, combining the lipophilic antiviral agent and a pharmacologically acceptable aqueous solvent to form a mixture, and forming liposomes from the lipophilic antiviral agent. The liposomes may be formed, for example, by sonication, extrusion or microfluidization. In one preferred embodiment, the combining step further comprises including in the combination a pharmacologically inactive lipophilic lipid. This inactive lipid can be, for example, a phosphatidylethanolamine, a sphingolipid, a sterol or a glycerophosphatide. The method also may include treating the liposomes with thio-antibodies to produce immunoliposomes, or including in the combination an lipophilic lipid which is, in part, comprised of a ligand. Thus, the liposome may include a ligand bound to a lipid substrate. In addition, the invention includes a method for treating retroviral and viral infections in a mammal, such as a human, by administering a sufficient quantity of the antiviral nucleoside analogues described herein to deliver a therapeutic dose of the antiviral agent to the mammal. In a preferred embodiment, the method is used to treat retroviral and viral infections in a mammal, wherein the retrovirus has become resistant to therapy with conventional forms of an antiviral agent. The present invention also includes a method for treatment of patients having strains of HIV that have developed resistance to AZT or reduced sensitivity to AZT, comprising the step of administering a composition of the present invention to such patient in an effective, retrovirus-inhibiting dosage. Also included in the present invention is a method for treating a viral infection in a mammal, comprising the step of administering an effective amount of a composition as described herein to a mammal. The infection may be a herpes simplex infection, and the composition may be phosphatidylacyclovir. Alternatively, the virus may be HIV retrovirus, and the composition may be 5'-palmitoylAZT. The method includes use where the retrovirus is a strain of HIV that has developed resistance to a nucleoside analogue. Also disclosed herein is a method for prolonging the antiviral effect of a nucleoside analogue in a mammal, comprising administering the nucleoside analogue to the mammal in the form of the nucleoside-lipid derivatives disclosed herein. Also disclosed is a method for avoiding or overcoming resistance of the retrovirus to nucleoside analogues through administering the analogue in the form of the lipid derivative compositions disclosed herein. Finally, the present invention includes use of these compositions in the preparation of a medicament for treatment of a human viral infection. Liposomal delivery of antiretroviral and antiviral drugs results in higher dosing of macrophage and monocyte cells which take up liposomes readily. The unique advantages of the present invention are that the lipid derivatives of the antiviral nucleosides are incorporated predominantly into the phospholipid layer of the liposome rather than in the aqueous compartment. This allows larger quantities of antiviral analogue to be incorporated in liposomes than is the case when water soluble phosphate esters of the nucleosides are used. Complete incorporation of the antiviral derivative into liposomes will be obtained, thus improving both the drug to lipid ratio and the efficiency of formulation. Further, there will be no leakage of the antiviral lipid analogues from the liposome during storage. Finally, liposomal therapy using these compositions allows larger amounts of antiviral compound to be delivered to the infected macrophage and monocyte cells. Therapy with liposomal compositions containing site specific ligands allows still greater amounts of antiviral compounds to be delivered with increased specificity. Another novel advantage of this invention is that each class of lipid derivatives of antiviral nucleosides disclosed below is believed to give rise directly to antiviral phosphorylated or non-phosphorylated nucleosides upon cellular metabolism. A further advantage of this invention is that the novel lipid derivatives are incorporated into the cell, protecting the cell for prolonged periods of time, up to or exceeding 48 hours after the drug is removed. These and other advantages and features of the present invention will become more fully apparent from the following description and appended claims. |
| PATENT EXAMPLES | Available on request |
| PATENT PHOTOCOPY | Available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |